February 24, 2021 – Multiple companies aim to surmount the limitations of CAR-T therapy by going beyond T-cells and engineering cell therapies based on natural killer (NK) cells or macrophages instead.
February 24, 2021 – Multiple companies aim to surmount the limitations of CAR-T therapy by going beyond T-cells and engineering cell therapies based on natural killer (NK) cells or macrophages instead.